Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation.

Autor: Kemp KL; School of Veterinary Science, The University of Queensland, 5391 Warrego Hwy, Gatton, Queensland, 4343, Australia., Skinner JE; School of Agriculture and Environmental Science, University of Southern Queensland, 487 - 35 West St, Darling Heights, Queensland, 4350, Australia., Bertin FR; School of Veterinary Science, The University of Queensland, 5391 Warrego Hwy, Gatton, Queensland, 4343, Australia.; College of Veterinary Medicine, Department of Veterinary Clinical Sciences, Purdue University, 625 Harrison St, West-Lafayette, Indiana, 47909, USA.
Jazyk: angličtina
Zdroj: Journal of veterinary internal medicine [J Vet Intern Med] 2025 Jan-Feb; Vol. 39 (1), pp. e17256. Date of Electronic Publication: 2024 Nov 22.
DOI: 10.1111/jvim.17256
Abstrakt: Background: Phenylbutazone is prescribed for laminitis-associated pain and decreases glucose and insulin responses to an oral glucose test (OGT) in horses with insulin dysregulation (ID).
Hypothesis/objectives: Investigate the effect of phenylbutazone administration on the enteroinsular axis in horses.
Animals: Sixteen horses, including 7 with ID.
Methods: Randomized cross-over study design, with horses assigned to treatment with phenylbutazone (4.4 mg/kg IV q24h) or placebo (5 mL 0.9% saline). On Day 9 of treatment, an OGT was conducted, followed by a 10-day washout period, administration of the alternative treatment, and repetition of the OGT. Glucose-dependent insulinotropic polypeptide (GIP), and active glucagon-like peptide 1 and 2 (aGLP-1 and GLP-2) concentrations were determined by ELISA. The effects of ID status and treatment on peptide concentrations were assessed using t tests and analyses of variance.
Results: Horses with ID had significantly higher maximum GIP concentrations (Cmax) than controls (median, 279.1; interquartile range [IQR], 117.5-319.4 pg/mL vs median, 90.12; IQR, 74.62-116.5 pg/mL; P = .01), but no significant effect of ID was detected on aGLP-1 and GLP-2 concentrations. In horses with ID, phenylbutazone treatment significantly decreased GIP Cmax compared with placebo (168.1 ± 59.26 pg/mL vs 242.8 ± 121.8 pg/mL; P = .04), but no significant effect of phenylbutazone was detected on aGLP-1 and GLP-2 concentrations.
Conclusion and Clinical Importance: Glucose-dependent insulinotropic polypeptide, aGLP-1 and GLP-2 do not mediate the decrease in glucose and insulin concentrations observed after phenylbutazone administration. Only GIP was repeatedly associated with ID status, calling into question the role of the enteroinsular axis in ID.
(© 2024 The Author(s). Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.)
Databáze: MEDLINE
Externí odkaz: